Ambrisentan, an endothelin receptor type A-selective antagonist, inhibits cancer cell migration, invasion, and metastasis

Several studies reported a central role of the endothelin type A receptor (ETAR) in tumor progression leading to the formation of metastasis. Here, we investigated the in vitro and in vivo anti-tumor effects of the FDA-approved ETAR antagonist, Ambrisentan, which is currently used to treat patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Kappes, Lucy, Amer, Ruba L., Sommerlatte, Sabine, Bashir, Ghada, Plattfaut, Corinna, Gieseler, Frank, Gemoll, Timo, Busch, Hauke, Altahrawi, Abeer, Al-Sbiei, Ashraf, Haneefa, Shoja M., Arafat, Kholoud, Schimke, Lena F., Khawanky, Nadia El, Schulze-Forster, Kai, Heidecke, Harald, Kerstein-Staehle, Anja, Marschner, Gabriele, Pitann, Silke, Ochs, Hans D., Mueller, Antje, Attoub, Samir, Fernandez-Cabezudo, Maria J., Riemekasten, Gabriela, al-Ramadi, Basel K., Cabral-Marques, Otavio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7522204/
https://www.ncbi.nlm.nih.gov/pubmed/32985601
http://dx.doi.org/10.1038/s41598-020-72960-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7522204/
https://www.ncbi.nlm.nih.gov/pubmed/32985601
http://dx.doi.org/10.1038/s41598-020-72960-1

Ejemplares similares